Fazlul H. Sarkar

47.0k total citations · 4 hit papers
466 papers, 33.7k citations indexed

About

Fazlul H. Sarkar is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Fazlul H. Sarkar has authored 466 papers receiving a total of 33.7k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Molecular Biology, 167 papers in Oncology and 143 papers in Cancer Research. Recurrent topics in Fazlul H. Sarkar's work include MicroRNA in disease regulation (62 papers), Cancer-related Molecular Pathways (52 papers) and Cancer Cells and Metastasis (40 papers). Fazlul H. Sarkar is often cited by papers focused on MicroRNA in disease regulation (62 papers), Cancer-related Molecular Pathways (52 papers) and Cancer Cells and Metastasis (40 papers). Fazlul H. Sarkar collaborates with scholars based in United States, India and China. Fazlul H. Sarkar's co-authors include Yiwei Li, Aamir Ahmad, Sanjeev Banerjee, Dejuan Kong, Zhiwei Wang, Bin Bao, Asfar S. Azmi, Subhash Padhyé, Shadan Ali and Yiwei Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Fazlul H. Sarkar

463 papers receiving 32.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review

2013 937 citations Asfar S. Azmi, Bin Bao et al. profile →
Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

2009 552 citations Yiwei Li, Timothy VandenBoom et al. Cancer Research profile →
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

2009 527 citations Zhiwei Wang, Yiwei Li et al. Cancer Research profile →
Multi-targeted therapy of cancer by genistein

2008 477 citations Sanjeev Banerjee, Yiwei Li et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fazlul H. Sarkar United States	100	18.9k	9.9k	9.0k	4.0k	2.7k	466	33.7k
Gautam Sethi Singapore	125	26.2k 1.4×	8.7k 0.9×	9.1k 1.0×	4.2k 1.0×	2.6k 0.9×	615	48.2k
Ajay Goel United States	89	16.0k 0.8×	8.8k 0.9×	10.0k 1.1×	5.8k 1.5×	2.4k 0.9×	461	29.1k
Hasan Mukhtar United States	114	14.6k 0.8×	4.2k 0.4×	4.1k 0.5×	10.3k 2.6×	3.5k 1.3×	557	41.3k
Zigang Dong United States	88	17.1k 0.9×	5.7k 0.6×	4.4k 0.5×	3.1k 0.8×	1.6k 0.6×	578	28.0k
Fadlo R. Khuri United States	85	14.7k 0.8×	9.9k 1.0×	4.5k 0.5×	1.8k 0.5×	5.6k 2.1×	486	27.1k
Jan H.M. Schellens Netherlands	91	16.1k 0.8×	22.6k 2.3×	3.7k 0.4×	2.7k 0.7×	6.4k 2.4×	882	41.1k
Andrew J. Dannenberg United States	86	7.8k 0.4×	5.6k 0.6×	4.4k 0.5×	1.7k 0.4×	1.9k 0.7×	273	24.3k
Ann‐Lii Cheng Taiwan	80	7.9k 0.4×	10.4k 1.0×	4.6k 0.5×	6.1k 1.5×	4.8k 1.8×	794	28.2k
Peng Huang China	82	18.0k 1.0×	5.8k 0.6×	7.4k 0.8×	1.2k 0.3×	2.9k 1.1×	329	31.3k
Richard Jove United States	94	21.5k 1.1×	21.9k 2.2×	6.9k 0.8×	6.2k 1.6×	2.7k 1.0×	264	40.4k

Countries citing papers authored by Fazlul H. Sarkar

Since Specialization

Citations

This map shows the geographic impact of Fazlul H. Sarkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fazlul H. Sarkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fazlul H. Sarkar more than expected).

Fields of papers citing papers by Fazlul H. Sarkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fazlul H. Sarkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fazlul H. Sarkar. The network helps show where Fazlul H. Sarkar may publish in the future.

Co-authorship network of co-authors of Fazlul H. Sarkar

This figure shows the co-authorship network connecting the top 25 collaborators of Fazlul H. Sarkar. A scholar is included among the top collaborators of Fazlul H. Sarkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fazlul H. Sarkar. Fazlul H. Sarkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Şahin, Kazım, Cemal Orhan, Mehmet Tuzcu, et al.. (2014). Comparative In Vivo Evaluations of Curcumin and Its Analog Difluorinated Curcumin Against Cisplatin-Induced Nephrotoxicity. Biological Trace Element Research. 157(2). 156–163. 43 indexed citations

Bao, Bin, Shadan Ali, Aamir Ahmad, et al.. (2014). Differentially Expressed miRNAs in Cancer-Stem-Like Cells: Markers for Tumor Cell Aggressiveness of Pancreatic Cancer. Stem Cells and Development. 23(16). 1947–1958. 30 indexed citations

Yin, Shuping, Liping Xu, R. Daniel Bonfil, et al.. (2013). Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 12(4). 491–498. 54 indexed citations

Bao, Bin, Zhiwei Wang, Shadan Ali, et al.. (2011). Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells. Cancer Prevention Research. 5(3). 355–364. 286 indexed citations

Li, Yiwei, Dejuan Kong, Zhiwei Wang, et al.. (2011). Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells. Cancer Prevention Research. 4(9). 1495–1506. 33 indexed citations

Wang, Zhiwei, Daming Gao, Hidefumi Fukushima, et al.. (2011). Skp2: A novel potential therapeutic target for prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1825(1). 11–17. 96 indexed citations

Jaiswal, Aruna S., Sanjeev Banerjee, Ritu Aneja, et al.. (2011). DNA Polymerase β as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer. PLoS ONE. 6(2). e16691–e16691. 44 indexed citations

Azmi, Asfar S., Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, & Fazlul H. Sarkar. (2010). Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations. Molecular Cancer Therapeutics. 9(12). 3137–3144. 76 indexed citations

Fan, Saijun, Qinghui Meng, Tapas Kumar Saha, Fazlul H. Sarkar, & Eliot M. Rosen. (2009). Low Concentrations of Diindolylmethane, a Metabolite of Indole-3-Carbinol, Protect against Oxidative Stress in a BRCA1-Dependent Manner. Cancer Research. 69(15). 6083–6091. 72 indexed citations

10.

Wang, Zhiwei, Asfar S. Azmi, Aamir Ahmad, et al.. (2009). TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway. Cancer Research. 69(7). 2757–2765. 69 indexed citations

11.

Jaiswal, Aruna S., Sanjeev Banerjee, Harekrushna Panda, et al.. (2009). A Novel Inhibitor of DNA Polymerase β Enhances the Ability of Temozolomide to Impair the Growth of Colon Cancer Cells. Molecular Cancer Research. 7(12). 1973–1983. 41 indexed citations

12.

Li, Yiwei, Timothy VandenBoom, Dejuan Kong, et al.. (2009). Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells. Cancer Research. 69(16). 6704–6712. 552 indexed citations breakdown →

13.

Ahmad, Aamir, Sanjeev Banerjee, Zhiwei Wang, et al.. (2009). Aging and Inflammation: Etiological Culprits of Cancer. Current Aging Science. 2(3). 174–186. 63 indexed citations

14.

Sarkar, Fazlul H., Yiwei Li, Zhiwei Wang, & Dejuan Kong. (2008). NF-κB Signaling Pathway and Its Therapeutic Implications in Human Diseases. International Reviews of Immunology. 27(5). 293–319. 189 indexed citations

15.

Xu, Hu, Yingjie Yu, Arun K. Rishi, et al.. (2005). Epidermal growth factor receptor (EGFR)–related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Molecular Cancer Therapeutics. 4(3). 435–442. 94 indexed citations

16.

Majumdar, Adhip P.N., Jianhua Du, James S. Hatfield, et al.. (2003). Expression of EGF-Receptor Related Protein (ERRP) Decreases in Gastric Mucosa During Aging and Carcinogenesis. Digestive Diseases and Sciences. 48(5). 856–864. 13 indexed citations

17.

Pierson, Christopher R., Megan S. Schober, Tracie Wallis, et al.. (2001). Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital mesoblastic nephroma. Human Pathology. 32(5). 513–520. 44 indexed citations

18.

Prasad, Ananda S., Bin Bao, Frances W.J. Beck, & Fazlul H. Sarkar. (2001). Zinc activates NF-κB in HUT-78 cells. Journal of Laboratory and Clinical Medicine. 138(4). 250–256. 79 indexed citations

19.

Rahman, Khalilur, et al.. (2000). Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells. Oncogene. 19(50). 5764–5771. 76 indexed citations

20.

Gupta, Sohan L., Arati Raziuddin, & Fazlul H. Sarkar. (1984). Receptors for Human Alpha Interferon: Are Gangliosides Involved?. Journal of Interferon Research. 4(3). 305–314. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact